New England Journal of Medicine· 2015Q1

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach, Hareth Nahi et al.

1,118citations
Q1SCImago
2015year

Short summary

Daratumumab monotherapy demonstrated a 36% overall response rate (ORR) in patients with relapsed or refractory multiple myeloma, with 15 patients achieving a partial response or better at the 16 mg/kg dose.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine